. 2018 Sep 3;13:2707–2720. doi: 10.2147/COPD.S167730

Table 4.

Costs and QALYs in the pooled REACT and RE²SPOND population (base case) and in the scenario analyses

Scenario (where applicable)	Treatment group	Total costs, £	Total QALYs	Incremental costs, £	Incremental QALYs	ICER, £ per QALY gained
Base case (deterministic)
	Triple inhaled therapy + ROF	19,524	5.23
	Triple inhaled therapy	16,016	5.09	3,508	0.14	24,976
Sensitivity analysis of the base case (probabilistic)
	Triple inhaled therapy + ROF	19,599	5.25
	Triple inhaled therapy	16,071	5.11	3,528	0.14	24,682
Scenario analyses varying post-hospitalization mortality (deterministic)
Scenario 1 Roberts et al (2002)²⁶	Triple inhaled therapy + ROF Triple inhaled therapy	19,883 16,358	5.31 5.17
Scenario 1 Roberts et al (2002)²⁶	Triple inhaled therapy + ROF Triple inhaled therapy	19,883 16,358	5.31 5.17	3,525	0.13	26,526
Scenario 2 Soler-Cataluña et al (2005)²⁷	Triple inhaled therapy + ROF Triple inhaled therapy	17,606 14,509	4.82 4.72
Scenario 2 Soler-Cataluña et al (2005)²⁷	Triple inhaled therapy + ROF Triple inhaled therapy	17,606 14,509	4.82 4.72	3,097	0.10	31,202
Scenario 3 Hartl et al (2016)²⁸	Triple inhaled therapy + ROF Triple inhaled therapy	20,578 17,027	5.46 5.34
Scenario 3 Hartl et al (2016)²⁸	Triple inhaled therapy + ROF Triple inhaled therapy	20,578 17,027	5.46 5.34	3,552	0.12	30,349
Scenario 4 Wildman et al (2009)²⁹	Triple inhaled therapy + ROF Triple inhaled therapy	15,760 12,545	4.38 4.18
Scenario 4 Wildman et al (2009)²⁹	Triple inhaled therapy + ROF Triple inhaled therapy	15,760 12,545	4.38 4.18	3,214	0.20	16,293
Scenario analysis in patient population with prior hospitalization (deterministic)
	Triple inhaled therapy + ROF	20,173	5.16
	Triple inhaled therapy	16,773	4.68	3,401	0.48	7,087

Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; ROF, roflumilast.